Europe Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)

List of Tables

The Europe botulinum toxin market was valued at US$ 1,174.94 million in 2023 and is expected to reach US$ 2,931.74 million by 2031; it is estimated to register a CAGR of 12.1% from 2023 to 2031 .

Aging Population in Europe Drives Europe Botulinum Toxin Market

The aging population in Europe presents a significant opportunity for market growth. As the region's demographic landscape shifts towards an older population, there is a parallel increase in demand for anti-aging treatments, such as botox. With older individuals seeking non-invasive solutions to maintain a youthful appearance, the demand for dermal fillers is increasing. As of January 1, 2023, the estimated population of the European Union was 448.8 million, with almost one-fifth (21.3%) of the population being 65 years of age or older. The EU's population reached a median age of 44.5 years on January 1, 2023. Advancements in filler technology that offer longer-lasting results and natural-looking outcomes cater to the preference of this demographic, further driving market expansion.

Europe Botulinum Toxin Market Overview

The Europe botulinum toxin market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global botulinum toxin market, and it is expected to record a strong growth rate during the forecast period. The market growth in the region is mainly attributed to product developments by botulinum toxin companies and an upsurge in the awareness of modern beauty standards among people from all age groups in European countries such as Germany, the UK, France, and Italy. In addition, advancements in healthcare systems are likely to propel the demand for botulinum toxin across the region in the coming years. The German healthcare sector utilizes advanced technologies in aesthetic and medical procedures. According to the ISAPS, a total of 605,942 nonsurgical aesthetic procedures were performed in the country in 2021, including 306,296 botulinum toxin treatments. Thus, the botulinum toxin market in Germany is expected to grow with the rising number of nonsurgical cosmetic procedures, and the growing awareness of minimally invasive procedures. Also, companies are launching products in the country for direct orders and customer delivery. In February 2023, Evolus, Inc. commercially launched Nuceiva in Germany for direct orders and delivery to customers.

Europe Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

Europe Botulinum Toxin Market Segmentation

The Europe botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the Europe botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of Europe botulinum toxin market share in 2023.

In terms of application, the Europe botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of Europe botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the Europe botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of Europe botulinum toxin market in 2023.

Based on country, the Europe botulinum toxin market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, and Galderma SA are some of the leading companies operating in the Europe botulinum toxin market.

Product Code: TIPRE00026638

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Botulinum Toxin Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
- 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
- 4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
- 4.3.1 Aging Population
4.4 Future Trends
- 4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - Europe Analysis

5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. Europe Botulinum Toxin Market Analysis - by Product

6.1 Overview
6.2 Botulinum Toxin A
- 6.2.1 Overview
- 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
- 6.3.1 Overview
- 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Botulinum Toxin Market Analysis - by Application

7.1 Overview
7.2 Medical
- 7.2.1 Overview
- 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.2.2.1 Europe Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
- 7.3.1 Overview
- 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 Europe Botulinum Toxin Market Breakdown, by Aesthetic

8. Europe Botulinum Toxin Market Analysis - by End User

8.1 Overview
8.2 Specialty and Dermatology Clinics
- 8.2.1 Overview
- 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
- 8.3.1 Overview
- 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Botulinum Toxin Market - Country Analysis

9.1 Europe: Botulinum Toxin Market
- 9.1.1 Europe: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Germany
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 Germany: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.1.3 Germany: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.1.4 Germany: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.1.4.1 Germany: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.1.4.2 Germany: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.1.5 Germany: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.2 United Kingdom
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 United Kingdom: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.3 United Kingdom: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.2.4 United Kingdom: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.2.4.1 United Kingdom: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.2.4.2 United Kingdom: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.2.5 United Kingdom: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.3 France
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 France: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.3 France: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.3.4 France: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.3.4.1 France: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.3.4.2 France: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.3.5 France: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.4 Italy
    - 9.1.1.4.1 Overview
    - 9.1.1.4.2 Italy: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.4.3 Italy: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.4.4 Italy: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.4.4.1 Italy: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.4.4.2 Italy: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.4.5 Italy: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.5 Spain
    - 9.1.1.5.1 Overview
    - 9.1.1.5.2 Spain: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.5.3 Spain: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.5.4 Spain: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.5.4.1 Spain: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.5.4.2 Spain: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.5.5 Spain: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.6 Rest of Europe
    - 9.1.1.6.1 Overview
    - 9.1.1.6.2 Rest of Europe: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.6.3 Rest of Europe: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.6.4 Rest of Europe: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.6.4.1 Rest of Europe: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.6.4.2 Rest of Europe: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.6.5 Rest of Europe: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

10.1 Merz Pharma GmbH & Co KGaA
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 AbbVie Inc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Ipsen SA
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Evolus Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Medytox Inc
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Galderma SA
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments

11. Appendix

11.1 About The Insight Partners